FDA Panel Debates Two Promising Cancer Drug Approvals
Published Date: 3/9/2026
Notice
Summary
The FDA is holding a public meeting on April 30, 2026, to discuss two cancer drugs: Camizestrant and Truqap (Capivasertib). Patients, doctors, and drug makers should pay attention because this meeting could affect how these medicines are approved and used. You can share your thoughts online until April 29, 2026, so don’t miss your chance to speak up!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in